We’re bringing innovation to the eye care space with integrin inhibition therapy, a new class of drugs for the treatment of ocular diseases.
Risuteganib (Luminate®), our primary investigational compound, is leading the charge with a novel mechanism of action that regulates multiple pathways of oxidative stress response which contribute to diseases such as intermediate nonexudative age-related macular degeneration (intermediate dry AMD) and diabetic macular edema (DME).
Risuteganib has successfully met the primary endpoint in a Phase 2 clinical trial for intermediate dry AMD. In addition, risuteganib has successfully met the clinical endpoints in two Phase 2 trials for DME. Data from these DME studies suggest the ability to treat patients who inadequately respond to the current standard of care by simultaneously targeting multiple oxidative stress response pathways to restore retinal homeostasis.
Allegro has also expanded the company’s anti-integrin portfolio with the new front-of-the-eye drug candidate ALG-1007. ALG-1007 is a topical therapeutic drug in development for potential use in patients with dry eye disease (DED), a condition affecting millions of people around the world.
As we focus on developing new treatment options for leading causes of blindness, we stay true to our company mission: helping eyecare professionals better serve their patients and improving patients’ quality of life through self-sufficient, functional vision. That’s our passion. The Allegro way.